UBS Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $196
Looking Into Ascendis Pharma's Recent Short Interest
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading
J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $200
Ascendis Pharma Price Target Raised to $200.00/Share From $168.00 by JP Morgan
Ascendis Pharma Is Maintained at Overweight by JP Morgan
Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $181
Top Gap Ups and Downs on Monday: NFLX, NVO, NVS and More
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week
Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $289
TD Cowen Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $162
Cantor Fitzgerald Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $200
Express News | Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $200
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $180
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
Why Is BioMarin Stock Trading Higher On Thursday?
Express News | Form 144 | Ascendis Pharma A/S(ASND.US) Officer Proposes to Sell 6.01 Million in Common Stocks
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today